key: cord-0803964-atxc5n1s
authors: Cron, Randy Q; Schulert, Grant S; Tattersall, Rachel S
title: Defining the scourge of COVID-19 hyperinflammatory syndrome
date: 2020-09-29
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30335-0
sha: b23e7a2674c0c6df29c439309715a879e2b175ee
doc_id: 803964
cord_uid: atxc5n1s

nan

It is abundantly clear that a subset of patients admitted to hospital with COVID-19 develop hyper inflammatory complications of severe COVID-19 infec tion or cytokine storm syndrome, 1,2 which is frequently fatal. What is less clear is how to define the cytokine storm syndrome in the context of severe COVID-19 infec tion. In The Lancet Rheumatology, Webb and colleagues 3 propose a set of clinical criteria for COVID-19-associated hyperinflammatory syndrome (cHIS). Development of such criteria are critically important for clinical trial enrol ment and for aiding clinicians in recognising patients who will benefit from therapy targeting the cytokine storm syndrome associated with COVID-19. One of the silver linings of the COVID-19 pandemic is the attention brought to cytokine storm syndromes in general. Cytokine storm syndrome refers to an umbrella of clinical states in which hyperinflammation and multiorgan disease arise from excessive cytokine release due to uncontrolled immune activation, and includes infectious, rheumatic, oncological, and immunotherapeutic aetiologies responsible for mortality in children and adults all over the world. Despite this, cytokine storm syn dromes are frequently under-recognised, 4 and the evidence base for treatment is lacking. There are both broad cyto kine storm syndrome criteria and disease-specific cyto kine storm syndrome criteria (appendix), none of which is perfectly sensitive or specific, thus adding to the complexities and difficulties in defining and diagnosing cytokine storm syndrome. The cytokine storm syndrome associated with COVID-19 is relatively unique among infectious cytokine storm syndromes with a propensity for early lung involvement in the form of acute respiratory distress syndrome and a predilection for clotting, as well as increased but less marked elevations in serum ferritin and interleukin-6 (IL-6) concentrations compared with other cytokine storm syndromes. 5 To estab lish criteria specific to COVID-19, Webb and colleagues did a systematic review of clinical and laboratory parameters linked to cHIS and compared those with other disease-associated cytokine storm syndrome criteria, particularly the 2016 systemic juvenile idiopathic arthritis macrophage activation syndrome criteria (appendix). 6 This approach lends credence to the concept that various hyperinflammatory syndromes triggered by different aetiologies, although not identical, share similar features and can be usefully categorised under the umbrella term of cytokine storm syndrome. 5 Webb and colleagues report that meeting two or more cHIS criteria place patients with COVID-19 at increased risk of mortality and requiring invasive mechanical ventila tion (odds ratio 1·6 [95% CI 1·2-2·1], p=0·0020, for mortality and 4·3 [3·0-6·0], p<0·0001, for mechanical ventilation). 3 The cHIS score also correlates with severity of oxygen requirement and risk for clinical deterioration of people with severe COVID-19. This finding is important for early recognition of patients with COVID-19 cytokine storm syndrome who might benefit from immuno modulatory or immunosuppressive approaches to treat the syndrome. 5 The rapidly changing approach to COVID-19 management, including the early initiation of gluco corticoids 7 during hospital admission, will probably modify components of the cHIS criteria, such as the presence of fever. This mirrors previous experience in children with systemic juvenile idiopathic arthritis in which IL-1 and IL-6 blocking biological treat ments diminished the sensitivity of systemic juvenile idio pathic arthritis macrophage activation syndrome criteria. 8 As knowledge about COVID-19 grows, evidence from a full range of medical specialties will need to be assimilated to further define and categorise the role of hyperinflammation and cytokine storm syndrome in COVID-19 mortality and morbidity.

One approach for diagnosing cytokine storm syndrome in general has been to simplify criteria for early recognition of cytokine storm syndrome in the setting of febrile individuals admitted to hospital based largely on hyperferritinaemia. 9 Indeed, algorithms in our own hospitals support obtaining ferritin on all patients admitted to hospital with COVID-19 to help identify signs of cytokine storm syndrome. Whether or not this reductionist methodology will be of value for COVID-19 cytokine storm syndrome remains to be seen. Moreover, there will probably need to be succes sive itera tions of the cHIS criteria to best define those who will bene fit from treatment that targets cyto kine storm syndromes in the context of ongoing developments in standard of care. Currently, Fernando Da Cunha/SPL clinicians worldwide are reliant on a collaborative approach of colleagues in various subspecialties who recog nise or diagnose and treat various cytokine storm syn dromes. A multidisciplinary team of intensivists, pulmonologists, haemato-oncologists, infectious disease experts, and paediatric and adult rheumatologists, among others, can be beneficial for aiding people with COVID-19 hyper inflammation in particular and to build on cytokine storm syndrome expertise in general. Perhaps, geneticists will be valuable as well in the near future, as we learn the genetic predispositions for cytokine storm syndrome development in the setting of infections and other triggers of disease. 10 For now, Webb and colleagues are the first to report cytokine storm syndrome clinical criteria specific to COVID-19 in the form of cHIS. 3 Importantly, these criteria are relatively standard assessments that are readily available, timely, and not cost-prohibitive for most countries. These criteria will need validation, but for now, should help clinicians to recognise cytokine storm syndrome in the setting of COVID-19 for early initiation of potentially life-saving immunotherapy.

RQC reports grants and personal fees from SOBI, and personal fees from Novartis and Pfizer during the conduct of the study. GSS reports personal fees from SOBI and Novartis

USA (RQC); Division of Rheumatology, Cincinnati Children's Hospital Medical

and Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield Children's Hospital NHS Foundation Trust

The rheumatologist's role in COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study

Pediatric macrophage activation syndrome, recognizing the tip of the iceberg

On the alert for cytokine storm: immunopathology in COVID-19

Haemophagocytic lymphohisticytosis-an underrecognized hyperinflammatory syndrome

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis

Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis

The genetics of macrophage activation syndrome